BioNxt Solutions (XTER:BXT) Moat Score: 3/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:BXT BioNxt Solutions Inc XTER:BXT
31 GF Score
Price €0.18
! 4 Warning Signs
View Full Analysis

What is BioNxt Solutions Moat Score?

BioNxt Solutions XTER:BXT -9.27% 31 Moat Score is 3 as of Aug. 13, 2026. GuruFocus rates XTER:BXT with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,026 Drug Manufacturers companies, BioNxt Solutions ranks better than 86.06% on this metric.

BioNxt Solutions has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

BioNxt Solutions has No Moat: BioNxt Solutions Inc lacks significant market leadership or intellectual property. The company operates in a competitive industry with low customer switching costs and limited brand strength, resulting in weak competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioNxt Solutions might have No Moat - Very weak/transient advantages.

BioNxt Solutions  (XTER:BXT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioNxt Solutions Moat Score Related Terms

XTER:BXT vs ZTS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNxt Solutions Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's Moat Score distribution charts can be found below:

* The bar in red indicates where BioNxt Solutions's Moat Score falls into.


XTER:BXT
31GF Score
BioNxt Solutions Inc XTER:BXT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
BioNxt Solutions (XTER:BXT) has a Moat Score of 3 as of Aug. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioNxt Solutions ranks #143 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is BioNxt Solutions' Moat Score too high?
BioNxt Solutions' current Moat Score is 3. Based on the distribution chart, BioNxt Solutions ranks #143 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioNxt Solutions has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' Moat Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioNxt Solutions ranks #143 out of 1026 companies for Moat Score. This places BioNxt Solutions in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BioNxt Solutions's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
BioNxt Solutions (XTER:BXT) has a current Moat Score of 3. The current Moat Score is 3. BioNxt Solutions' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioNxt Solutions (XTER:BXT), the current Moat Score is 3 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioNxt Solutions Business Description

Address 1928 Linden Road, Vancouver, BC, CAN, V6M 1E7
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
31GF Score

Get the complete analysis for XTER:BXT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price